As a result of compensation payments that Green Cross of Japan has agreed to make to hemophiliacs who were infected by HIV through use of the firm's blood products, Green Cross expects to report recurring losses for the current fiscal year of over 5 billion yen ($46 million), and is to implement a restructuring program.
The firm has indicated that it will close four plants in Japan and reduce its workforce to 2,000 from the current 2,400 within three to four years. The plant closures will be made by 2000 and the land will be sold.
Green Cross faces compensation payments of around 24 billion yen in total, and has asked the Sakura Bank, its leading creditor, for financial support for the restructuring program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze